Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

2025/04/17 by Tom Loosli, Carolyn Bolton‐Moore, Lydia Buzaalirwa +20 · 1 voice · 10 citations
Immunology and Microbiology · Medicine · #HIV Research and Treatment #HIV/AIDS Research and Interventions #HIV/AIDS drug development and treatment

paper · pdf · doi:10.1093/cid/ciaf204

openalex publication_date 2025/04/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30

Abstract

Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.

Cited by

• A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study

Discussions

• #IDsky Found this DTG-RESIST article fascinating (1/5 w/resistance in subsaharan Africa w/virologic failure on DTG) doi.org/10.1093/cid/... Especially seeing the NEJM article showing superiority with [bsky, 5 points, 0 comments]

Related

• HIV drug resistance: problems and perspectives
• HIV drug resistance: problems and perspectives
• Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
• Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
• The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study